<DOC>
	<DOCNO>NCT03061331</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , placebo-controlled , multicenter , crossover study evaluate efficacy LUM/IVA subject CF 12 year age old least one A455E mutation .</brief_summary>
	<brief_title>Lumacaftor/Ivacaftor Combination Therapy Subjects With CF Who Have A455E CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female confirm diagnosis CF All subject must A455E mutation least 1 CFTR allele ; 10 subject may F508del mutation 1 CFTR allele . Forced expiratory volume one second ( FEV1 ) ≥30 % predict ≤90 % predict Screening Visit , base Global Lung Function Initiative ( GLI ) 2012 multi ethnic allage reference equation . Stable CF disease judge investigator . Willing remain stable medication regimen CF 4 week Day 1 Follow Visit . History comorbidity review Screening Visit , opinion investigator , might confound result study pose additional risk administer study drug subject . A G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N , S549R , R117H mutation least one CFTR allele . Pregnant breastfeeding . Any abnormal laboratory value Screening Visit . History cataract/lens opacity , evidence cataract/lens opacity determine clinically significant ophthalmologist optometrist ophthalmologic examination Screening Visit . Use strong inhibitor strong inducer CYP3A , include consumption certain herbal medication certain fruit fruit juice , within 14 day Day 1 Sexually active subject reproductive potential willing follow contraception requirement</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>